Benzinga · Aug 25, 2026
FDA Approves Drug To Treat HIV Infection in Newborns
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns

NYSE · PFE
Healthcare · Drug Manufacturers - General
$27.96
Down-$0.06 (-0.21%)
Updated Aug 31, 2026, 7:15 AM
SID Score
7.5/10
Composite research score
Smart Money
74/100
Bullish
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PFE closed at $27.96 after 20 trading sessions, up 11.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $28.00 | $28.02 | $27.77 | $27.96 | 27.18M |
| Aug 27, 2026 | $27.97 | $28.18 | $27.83 | $28.02 | 31.17M |
| Aug 26, 2026 | $28.44 | $28.50 | $28.145 | $28.30 | 35.07M |
| Aug 25, 2026 | $27.915 | $28.58 | $27.84 | $28.57 | 31.92M |
| Aug 24, 2026 | $28.10 | $28.1561 | $27.81 | $27.97 | 23.85M |
| Aug 21, 2026 | $27.77 | $28.425 | $27.655 | $28.07 | 37.11M |
| Aug 20, 2026 | $28.00 | $28.16 | $27.645 | $27.79 | 29.3M |
| Aug 19, 2026 | $27.60 | $28.435 | $27.58 | $28.24 | 59.8M |
| Aug 18, 2026 | $27.15 | $27.395 | $27.10 | $27.25 | 34.66M |
| Aug 17, 2026 | $26.76 | $27.02 | $26.55 | $26.87 | 29.26M |
| Aug 14, 2026 | $26.66 | $26.915 | $26.42 | $26.79 | 23.17M |
| Aug 13, 2026 | $26.49 | $26.95 | $26.41 | $26.80 | 35.36M |
| Aug 12, 2026 | $26.385 | $26.435 | $26.18 | $26.31 | 32.59M |
| Aug 11, 2026 | $26.94 | $27.20 | $26.47 | $26.62 | 37.94M |
| Aug 10, 2026 | $26.585 | $27.19 | $26.52 | $27.05 | 49.79M |
| Aug 7, 2026 | $26.22 | $26.76 | $26.0503 | $26.76 | 42.74M |
| Aug 6, 2026 | $26.01 | $26.20 | $25.81 | $26.20 | 51.07M |
| Aug 5, 2026 | $25.50 | $25.81 | $25.30 | $25.81 | 47.06M |
| Aug 4, 2026 | $25.04 | $25.64 | $24.70 | $25.41 | 62.19M |
| Aug 3, 2026 | $25.15 | $25.39 | $24.865 | $25.03 | 41.78M |
The latest Smart Investors Daily articles mentioning PFE.
PFE research
Company profile and research snapshot.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Jul 13, 2026 | Guggenheim | Buy | — |
| Jul 13, 2026 | BMO Capital | Outperform | — |
| Jul 10, 2026 | B of A Securities | Neutral | — |
| Jul 8, 2026 | JP Morgan | Neutral | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns
Benzinga · Aug 25, 2026
Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Yahoo · Aug 22, 2026
Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.
Yahoo · Aug 21, 2026
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning PFE.